Objectives. To determine whether renal function predicts the development of cardiovascular disease and other arterial vascular events in patients with SLE.
Introduction
SLE is a multi-system, auto-immune, connective-tissue disorder. It predominantly affects young women, and peaks between the ages of late teens and early 40s [1] . SLE patients are at much higher risk for cardiovascular disease (CVD), which significantly contributes to morbidity and mortality in this patient population [2, 3] . Women aged 4450 years with SLE have a dramatic 50-fold increase in CVD risk compared with age-and gender-matched population controls [2, 3] .
Renal involvement is a common manifestation that occurs in 5075% of patients during the course of SLE [4, 5] . Chronic kidney diseases have been associated with increased risk of CVD in a variety of populations [1, 69] . Recent studies reported that even mildly impaired kidney functions significantly increased the risk of CVD [9, 10] . An accurate measurement of kidney function is, therefore, a newly described important risk factor that must be included in the assessment of CVD risks.
The estimated glomerular filtration rate (eGFR), derived from serum creatinine (Scr) and age using the Modification of Diet in Renal Disease (MDRD) equation [6, 11, 12] , has been used as an indirect measure of renal function. Normal eGFR in a healthy adult aged 2030 years is $125 ml/min/1.73 m 2 and declines by 1 ml/min/1.73 m each year [12] . A number of studies have shown that reduced eGFR is associated with increased risks of CVD [10, 1320] and all-cause and CVD-related mortality [9, 10] . Associations between renal function and CVD have not been studied in patients with SLE. Thus, the purpose of this study was to develop a model, using baseline eGFR, to predict arterial/vascular events in SLE patients. We hypothesized that low eGFR early in the course of disease would independently increase the risk of arterial events after adjusting for demographic, clinical and traditional CVD risk factors.
Patients and methods

Subjects
Patients were selected from the patient database at the University of Toronto Lupus Clinic (UTLC). Since 1970, the UTLC has prospectively followed patients who fulfilled at least four of the 1971 or 1982 ACR classification criteria or three ACR criteria plus histological evidence of SLE on renal or skin biopsy. All patients gave their informed consent according to the Declaration of Helsinki and were followed according to a standard protocol. The study had continuous approval from the University Health Network Research Ethics Board. A cohort of 631 female subjects who were seen and followed at UTLC within 1 year of diagnosis of SLE (an inception cohort), between the years 1970 and 2007, were selected from the UTLC patient database. Subjects were excluded if they had <1 year of follow-up (11 patients) or had less than three measurements of Scr (116 patients). A total of 437 female subjects met the inclusion criteria and thus were included in this study.
Assessment of kidney function
The eGFR was calculated for each subject at each visit using the abbreviated MDRD Study Group formula: GFR = 186 Â (Scr) À1.154 Â age À0.203 Â (0.742 female) Â (1.210 if AfricanAmerican), where Scr is measured in mg/dl and age in years [11] . A renal flare was defined as an increase in Scr of 540 mmol/l or an increase in 24-h urine protein excretion of 51 g/day between two consecutive visits and/or a new pathological renal biopsy of World Health Organization (WHO) Class III, IV or V lupus nephritis. Stage 4/5 chronic kidney disease was defined as Scr of >200 mmol/l and/or eGFR <15 ml/min/1.73 m 2 and/or dialysis for >6 months or having a kidney transplant [21] .
CVD risk factors and outcomes
Data on CVD risk factors were collected and included: systolic and diastolic blood pressures (BPs), smoking history, BMI, blood lipids, history of diabetes and the use and cumulative dose of steroids. Mean arterial pressure was calculated using the sum of diastolic pressure and one-third of the pulse pressure. For each subject, the corresponding time-averaged values were calculated for each variable for every 6-month period during the follow-up. Arterial vascular events including myocardial infarction, angina, transient ischaemic attacks, cerebral vascular accidents and other arterial events were documented for up to 15 years since the first visit. Patients who had arterial events during the course of follow-up were compared with those who had no events. Since arterial/ vascular events are reported as following a bimodal curve with early (within the first 3 years after SLE diagnosis) and then late events (after 7 years) [22, 23] , patients with arterial events were further sub-categorized into events that occurred within or after 3 years since the first visit (events <3 year or events 53 year). Data on medications and CVD risk factors and lupus-specific risk factors for CVD such as disease duration, use of CSs and disease activity were recorded for each patient. Data on menopausal status and the prevalence of APS were also collected. APS was defined as presence of LA or aCL >40 GPL or MPL (1 GPL or MPL is equivalent to 1 mg of affinity purified IgG or IgM ideotypes of aCL) for at least two visits that were 3 months apart in addition to vascular thrombosis in any organ or tissue or pregnancy event as defined by the Sapporo cirteria for APS [24] .
SLE disease activity and damage
Disease activity was determined by prospectively recording the SLEDAI 2000 (SLEDAI-2K) [25] . SLEDAI encompasses CNS and musculoskeletal symptoms; urinary abnormal findings such as casts, haematuria, proteinuria and pyuria; skin changes; mucous membrane involvement; serositis such as pleurisy and pericarditis; low complement levels; increased DNA binding; haematology involvement; and fever. SLEDAI serves as a monitoring tool for assessment of severity of SLE and efficacy of its treatment [26] . Exacerbations of SLE are paralleled by an increase in SLEDAI of at least 3 points [27] for mild flare and more than 5 points for severe flare [28] . SLEDAI of at least 6 points is considered an active disease [26] . An adjusted mean SLEDAI score was also calculated to describe the disease activity over time [29] .
SLICC-damage index (SDI) [30] was used to assess cumulative and irreversible damage due to SLE, its treatment or other illnesses in 12 organ systems (ocular, neuropsychiatric, renal, pulmonary, cardiovascular, peripheral vascular, gastrointestinal, musculoskeletal, skin, gonadal failure, diabetes and malignancies). SDI was recorded at regular intervals to describe and follow the cumulative damage over time.
Statistical analysis
Statistical analysis was performed by SPSS (1983, version 12; SPSS Inc., Chicago, IL, USA) and SAS (version 9.1; SAS Institute, Cary, NC, USA). When comparing two groups, the t-test and the Wilcoxon rank-sum test were used for continuous variables, and the chi-square test and Fisher's exact test were employed for categorical variables. The association between time to arterial events and patient characteristics, including baseline eGFR and CVD risk factors, was investigated via the Cox proportional hazards model, where the final multivariate model was constructed based on the significance of univariate analyses and also the clinical importance of the variables. Assumptions such as normality and proportional hazards, where applicable, were examined before model application. For all tests and confidence intervals, the significance level was set at 5%.
Results
An inception cohort of 437 female patients followed for >1 year, who had at least three measurements of Scr, were included in the analyses. Baseline characteristics of the study subjects are reported in Table 1 . The mean (S.D.) age was 35.5 (13.9) years. The majority of patients were Caucasian followed by AfricanAmericans and Asian and 38.7% were post-menopausal. Mean BMI was at the upper end of the normal range, mean eGFR, systolic and diastolic BPs and serum cholesterol were all within the normal range. Mean (S.D.) baseline SLEDAI-2K score for the cohort was 11.1 (8.44). The mean (S.D.) average follow-up duration for the cohort was at 11.3 (8.2) years and 6% (n = 26) met the criteria for APS.
During the follow-up period, 58 patients (13.3%) had arterial events, 224 (51.3%) had renal involvements and, among them, 17 deteriorated to end-stage renal disease (3.9%): on average, 6 years from the time of inception (baseline visit). During the follow-up period, 112 (25.6%) patients had renal flares and 353 (80.3%) had non-renal flares. The mean (S.D.) arterial pressure was at 92.5 (9.5) mmHg, the adjusted mean (S.D.) SLEDAI-2K was at 5.1 (3.4) and the SDI score at final assessment was at 1.6 (2.0). Upon final assessment, 59 died (13.5%) and 133 (30.4%) were lost to follow-up, with a median follow-up duration of 8.8 years (inter-quartile range 3.414.3 years). The time to death in those who died was 11.6 (6.9) years.
Assessment of cardiovascular risk factors
The presence of CVD risk factors as defined by the Framingham Heart Study during the follow-up period are reported in Table 2 . High proportions of patients had elevated levels of blood cholesterol and triglycerides at some point during the follow-up period. One-third of the patients were cigarette smokers and 29% had family history of CVD. Among the prescription medications, the mean (S.D.) average daily dose of steroids was 13.2 (8.25) mg, angiotensin-converting enzyme/angiotensin receptor blocker inhibitors were given to 24.5% of patients, 41% were on lipid-lowering medications and 14.6% were on anti-coagulants (Table 2) . Anti-malarial drugs and AZA were most commonly prescribed for SLE (anti-malarial: 75.1%; AZA: 38%). CYC was only used by 8.7% of our patients as our centre has previously shown similarly good outcomes with AZA [31] . Oral contraceptives was used by 31.4% (n = 137) and 14.2% were using HRT.
Comparisons between patients with and without CVD events A total of 58 events were reported during the follow-up period. Nearly half of all events were thrombotic ischaemic attacks/stroke (n = 21) followed by angina (n = 16) and myocardial infarction (n = 15), four subjects had peripheral vascular disease and two had heart failure.
Patients with arterial events were compared with those who had no events ( Table 3 ). The duration of follow-up was similar for both patients with and without arterial events. However, at baseline, patients with arterial events were significantly older and had significantly lower eGFR, higher SLEDAI-2K, higher prevalence of APS and higher systolic and diastolic BPs compared with patients with no previous arterial events. During the course of follow-up, patients with arterial events had significantly more renal and non-renal flares and significantly higher incidence of end-stage renal disease, higher SDI score and higher mortality rate than patients with no previous arterial events. In addition, the time-averaged cholesterol and mean arterial pressure were significantly higher in patients with arterial events compared with patients with no previous arterial events (Table 3) . Patients with arterial events were more likely to be on lipid-lowering medications and to use anti-coagulant medications compared with those without arterial events. Patients with arterial events were further subcategorized into those who had events within the first 3 years and those who had events after the 3 years of follow-up. Characteristics of these subgroups are reported in Table 3 . Patients who had arterial events within the first 3 years of their follow-up had a significantly lower baseline eGFR and were significantly older than those who had arterial events after 3 years of follow-up. The baseline SLEDAI-2K, dsDNA antibody levels, prevalence of APS, BP and cholesterol were similar between the two groups. Patients with arterial events within the first 3 years of follow-up had a significantly shorter follow-up duration and a significantly lower SDI score on final assessment than those who had arterial events after the 3 years of follow-up (Table 3) . Patients who were younger than the mean age of the patients with arterial events and those who had arterial events within the first 3 years of follow-up, had a significantly lower mean (S.D.) baseline eGFR than the similar age group of patients who had arterial events after the 3 years of follow-up [61.5 (26.3) vs 85.2 (20.8); P < 0.05].
Multivariate Cox regression analysis
The following variables were included in the multivariate model: age, baseline eGFR, baseline SLEDAI-2K, cholesterol and systolic BP (Table 4) . Baseline eGFR, age and baseline SLEDAI-2K were significantly associated with the risks of arterial events [eGFR: hazard ratio (HR) = 0.986, 95% CI 0.974, 0.997; age: HR = 1.032, 95% CI 1.012, 1.052; SLEDAI: HR = 1.041, 95% CI 1.015, 1.067]. For a typical female SLE patient, controlling for other risk factors, every 10 ml/min/1.73m 2 increase of baseline eGFR decreased having an arterial event by 14% and every 10-year increase in age increased the risk of arterial event by 32% (Table 4) .
Discussion
In this cohort of young women with SLE, we found that a lower eGFR at the time of SLE diagnosis was independently and significantly associated with arterial vascular events. Further reductions in eGFR accelerated the time to events; patients with significantly lower eGFR developed arterial events within the first 3 years since the initial diagnosis of lupus. Several studies have shown increased risk of CVD for patients with impaired kidney functions. Go et al. [10] showed an increased and graded CVD risks associated with eGFR <60 ml/min/1.73 m 2 . In the National Health and Nutrition Examination Survey, eGFR <70 ml/min/1.73 m 2 was associated with a 51% increase in mortality from CVD [14] . In the Atherosclerosis Risk in Communities Study, an eGFR of 1559 ml/min/1.73 m 2 led to a 38% increase in CVD risk [15] . Nevertheless, most of the studies focused on older adults (aged 565 years), patients with existing vascular diseases or at high risks for CVD [10, 1420, 3236] . Our study is the first to investigate the role of impaired kidney function and CVD in SLE patients. The present study also confirmed the findings of other studies by showing that in young women with SLE, similarly to other populations, moderate reduction in eGFR is predictive of high risk for CVD. The mechanism by which impaired kidney function could lead to increased risk for CVD is not clear [32] . Lupus alone has been suggested as a risk factor for the development of atherosclerosis, independent from the traditional risk factors for CVD [2, 3] . The chronic inflammatory state of lupus is postulated to cause endothelial and vascular damage [33] . Impaired kidney function has also been linked to chronic inflammation [34, 35] , abnormal apolipoprotein levels [38] , elevated plasma homocysteine [35] , increased coagulability [34] , anaemia [36] , left ventricular hypertrophy [37] , endothelial dysfunction [38] and arterial stiffness [39] . Therefore, it is logical to think that the combination of SLE and impaired kidney function could result in an increased risk for CVD. However, it is important to note that low eGFR is often clustered with other traditional risk factors for CVD such as history of hypertension and hyperlipidaemia [10] . In the present study, hypertension was more prevalent in patients with impaired kidney function: 97% of these patients also had abnormal blood lipid profile, both risk factors for CVD. It has not been clear whether the impaired kidney function is the cause for these metabolic abnormalities, resulting in an increased risk for CVD or the metabolic abnormalities are SLE related and independent from the impaired kidney function. However, the multivariate regression analysis in this study showed that despite the coexistence of risk factors for CVD, reduced eGFR was independently associated and was predictive of CVD in SLE. This is consistent with the increasing evidence that chronic kidney disease should be included as an important risk factor for future CVD in SLE [10] . In addition to modification of the traditional risk factors for atherosclerotic diseases, our study supports the importance of early aggressive management of impaired kidney functions in order to prevent future CVD.
Our study has several strengths. Our data collection was comprehensive and was designed to address a The HR noted is a 3.2% increase in the risk of arterial events for an increase in age by 1 year. This will translate to a 32% increase for every 10-year increase in age. b The HR noted is a 1.4% decrease in the risk of arterial events for an increase in eGFR by 1 U/year. This will translate to a 14% increase for every 10-U decrease in eGFR. HR: hazard ratio.
www.rheumatology.oxfordjournals.org larger number of confounding factors. All participants were young women, who are particularly vulnerable to the early attacks of cardiovascular and renal complications as a result of lupus [2, 3] . The homogeneity of the study reduced bias. However, there are some limitations. The patients for this study were all women and selected from a tertiary-care facility and may not be fully representative of the general SLE population. The measures of renal function were restricted to eGFR. We had no other measures such as cystatin-C or microalbuminuria, which may be better markers of chronic kidney disease and better predictors for CVD [40] . More consistent measures of proteinuria should be considered in future studies for a full picture of renal function.
In conclusion, we demonstrated that a moderate reduction in eGFR, older age and high SLEDAI-2K at the time of inception significantly contribute to high CVD risks in women living with SLE, independent from other traditional or SLE-related CVD risk factors. Early management of impaired kidney function may decrease the risk of CVD in SLE.
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